A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression
This historical record does not confirm current site availability.
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- United Kingdom
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This is historical registry information. What is the current study status and protocol?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 90
- Sponsor
- Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2017-002232-16
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression
Recruitment & locations
United Kingdom
Registry details
- United Kingdom — Prematurely Ended
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd, a pharmaceutical company.
Is this study still recruiting?
The historical registry lists this study as terminated.
